Advanced gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC) require treatment plans that are specifically TAILORed for each patient. Understanding the impact of HER2 and the latest advancements in assessment and management are key elements to effectively target tumors and optimize outcomes in advanced GEA and BTC.
The TAILOR Community of Care site is funded by an independent medical education grant from Jazz Pharmaceuticals. The following site is not affiliated with the TAILOR educational initiative and MLG is not responsible for its content.